• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他汀类药物是否抑制结直肠癌患者奥沙利铂诱导的周围神经病?一项单中心观察性研究。

Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.

机构信息

Department of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

出版信息

Support Care Cancer. 2023 Oct 28;31(12):660. doi: 10.1007/s00520-023-08134-2.

DOI:10.1007/s00520-023-08134-2
PMID:37897532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10613143/
Abstract

BACKGROUND

Oxaliplatin-induced peripheral neuropathy (OIPN) is a common and dose-limiting toxicity that markedly limits the use of oxaliplatin and affects quality of life. Statins have been shown to exert neuroprotective effects in preclinical settings. The aim of the present study was to clarify whether statins prevented OIPN in patients with colorectal cancer (CRC) receiving adjuvant CAPOX therapy.

METHODS

We examined 224 patients who received adjuvant CAPOX therapy for CRC between July 2010 and December 2021 at our hospital. Patients were divided into "Statin" and "Non-statin" groups based on statin use. Details on and the adverse events of adjuvant CAPOX therapy were examined in association with statin use.

RESULTS

Thirty-one patients (14%) were treated with statins. There were no intergroup differences in the relative dose intensity or number of CAPOX cycles between the Statin and Non-statin groups. In total, 94% of patients in the Statin group and 95% of those in the Non-statin group developed OIPN (p=0.67). The severity of OIPN was similar between the two groups (p=0.89). The frequency of treatment delays in CAPOX did not significantly differ between the Statin and Non-statin groups (16% vs. 11%, p=0.45).

CONCLUSIONS

The efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study. Further studies are needed to confirm the present results.

摘要

背景

奥沙利铂诱导的周围神经病变(OIPN)是一种常见的剂量限制毒性,显著限制了奥沙利铂的应用,并影响了生活质量。他汀类药物已被证明在临床前环境中具有神经保护作用。本研究旨在阐明他汀类药物是否能预防接受辅助 CAPOX 治疗的结直肠癌(CRC)患者的 OIPN。

方法

我们检查了 2010 年 7 月至 2021 年 12 月期间在我院接受辅助 CAPOX 治疗的 224 例 CRC 患者。根据他汀类药物的使用情况,将患者分为“他汀类”和“非他汀类”两组。检查了辅助 CAPOX 治疗的详细信息和不良事件与他汀类药物使用的关系。

结果

31 例(14%)患者接受了他汀类药物治疗。他汀类药物组和非他汀类药物组之间,CAPOX 的相对剂量强度或周期数均无组间差异。他汀类药物组 94%的患者和非他汀类药物组 95%的患者发生 OIPN(p=0.67)。两组 OIPN 的严重程度相似(p=0.89)。CAPOX 治疗的延迟频率在他汀类药物组和非他汀类药物组之间没有显著差异(16%比 11%,p=0.45)。

结论

在本研究中,他汀类药物在辅助 CAPOX 治疗中减轻 OIPN 的疗效并不明显。需要进一步的研究来证实目前的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7eb/10613143/9886aba02e36/520_2023_8134_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7eb/10613143/9886aba02e36/520_2023_8134_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7eb/10613143/9886aba02e36/520_2023_8134_Fig1_HTML.jpg

相似文献

1
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.他汀类药物是否抑制结直肠癌患者奥沙利铂诱导的周围神经病?一项单中心观察性研究。
Support Care Cancer. 2023 Oct 28;31(12):660. doi: 10.1007/s00520-023-08134-2.
2
Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.在氟嘧啶基础上加用奥沙利铂辅助治疗结直肠癌与周围神经感觉功能和生活质量的长期损害相关。
Acta Oncol. 2016 Sep-Oct;55(9-10):1227-1235. doi: 10.1080/0284186X.2016.1197420. Epub 2016 Aug 23.
3
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.奥沙利铂诱导的周围神经病变的控释羟考酮的疗效和耐受性以及晚期结直肠癌患者 FOLFOX 治疗的延长。
Support Care Cancer. 2014 Jun;22(6):1579-84. doi: 10.1007/s00520-014-2132-4. Epub 2014 Jan 24.
4
Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.卡培他滨和奥沙利铂辅助治疗老年结直肠癌患者。
Oncology. 2022;100(11):576-582. doi: 10.1159/000527012. Epub 2022 Oct 17.
5
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.奥沙利铂辅助化疗治疗结直肠癌患者的长期神经病变和生活质量。
Acta Oncol. 2019 Apr;58(4):398-406. doi: 10.1080/0284186X.2018.1556804. Epub 2019 Jan 14.
6
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.III期和高危II期结直肠癌患者序贯辅助化疗的可行性:采用3个月的奥沙利铂方案,随后3个月的卡培他滨:JSWOG-C2研究
Drug Des Devel Ther. 2016 Nov 23;10:3827-3835. doi: 10.2147/DDDT.S112322. eCollection 2016.
7
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.结肠癌辅助奥沙利铂-氟嘧啶联合治疗 3 个月与 6 个月(SCOT):一项国际性、随机、III 期、非劣效性试验。
Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.
8
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).奥沙利铂辅助化疗后复发的结直肠癌患者中重新引入 FOLFOX 或 CAPOX 联合或不联合贝伐珠单抗的疗效评价(REACT 研究)。
Int J Clin Oncol. 2020 Aug;25(8):1515-1522. doi: 10.1007/s10147-020-01701-1. Epub 2020 May 14.
9
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.高危 II 期结直肠癌辅助化疗 3 个月与 6 个月的持续时间和效果评估:TOSCA 随机临床试验的亚组分析。
JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486.
10
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.III 期随机、安慰剂对照、双盲研究显示,单唾液酸四己糖神经节苷脂可预防 II/III 期结直肠癌奥沙利铂诱导的周围神经毒性。
Cancer Med. 2020 Jan;9(1):151-159. doi: 10.1002/cam4.2693. Epub 2019 Nov 13.

本文引用的文献

1
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.奥沙利铂辅助治疗 III 期结肠癌所致周围神经病的潜在中介物:CALGB(联盟)/SWOG80702 研究结果。
J Clin Oncol. 2023 Feb 10;41(5):1079-1091. doi: 10.1200/JCO.22.01637. Epub 2022 Nov 11.
2
Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life: Practical lessons from a prospective cross-sectional, real-world study.奥沙利铂引起的神经病变与结直肠癌患者的生活质量:一项前瞻性横断面真实世界研究的实践经验
World J Clin Cases. 2022 Apr 6;10(10):3101-3112. doi: 10.12998/wjcc.v10.i10.3101.
3
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.
利用大数据识别奥沙利铂诱导的周围神经病的预防药物。
Biomed Pharmacother. 2022 Apr;148:112744. doi: 10.1016/j.biopha.2022.112744. Epub 2022 Feb 28.
4
Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review.化疗引起的周围神经病与糖尿病:范围综述
Curr Oncol. 2021 Aug 19;28(4):3124-3138. doi: 10.3390/curroncol28040273.
5
Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence.奥沙利铂诱导的周围神经病变的治疗药物;实验和临床证据
Int J Mol Sci. 2021 Jan 30;22(3):1393. doi: 10.3390/ijms22031393.
6
Platinum accumulation in oxaliplatin-induced peripheral neuropathy.奥沙利铂诱导的周围神经病中的铂蓄积。
J Peripher Nerv Syst. 2021 Mar;26(1):35-42. doi: 10.1111/jns.12432. Epub 2021 Jan 27.
7
Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.奥沙利铂诱导的周围神经病:临床特征、发病机制、预防及治疗。
J Neurol. 2021 Sep;268(9):3269-3282. doi: 10.1007/s00415-020-09942-w. Epub 2020 May 30.
8
Statins and Neuropathic Pain: A Narrative Review.他汀类药物与神经性疼痛:一项叙述性综述。
Pain Ther. 2020 Jun;9(1):97-111. doi: 10.1007/s40122-020-00153-9. Epub 2020 Feb 4.
9
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.结直肠癌的流行病学:发病率、死亡率、生存率及危险因素。
Prz Gastroenterol. 2019;14(2):89-103. doi: 10.5114/pg.2018.81072. Epub 2019 Jan 6.
10
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.日本结直肠癌学会(JSCCR)2019 年结直肠癌治疗指南。
Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15.